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matory bowel disease (IBD) have been reported for epidemiology, disease presentation, disease course
and complications, medical and surgical therapies, adherence, psychosocial functioning, and psychiatric
co-disorders. While for some factors evidence is rather good, for others data are conflicting. Gastroen-
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has been shown to have deleterious effects, and (2) awareness of gender-specific symptoms and disease
severity allows initiation of early and adequately tailored treatment. This might prevent development
of complications. And (3) insights into gender-specific differences in terms of treatment and adherence
to treatment can improve disease management and foster a more individualized treatment approach. In
this review, we summarize current knowledge about gender-specific differences in IBD and highlight the
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Abstract
Immune-mediated diseases typically show a female prepon-
derance. Looking at all autoimmune diseases combined, 8 of 
10 patients are females. Although not as prominent, gender 
differences in inflammatory bowel disease (IBD) have been 
reported for epidemiology, disease presentation, disease 
course and complications, medical and surgical therapies, 
adherence, psychosocial functioning, and psychiatric co-dis-
orders. While for some factors evidence is rather good, for 
others data are conflicting. Gastroenterologists dealing with 
IBD patients in daily clinical practice should be aware of gen-
der-specific issues for the following reasons: (1) mispercep-
tion of disease presentation potentially delays IBD diagnosis, 
which has been shown to have deleterious effects, and (2) 
awareness of gender-specific symptoms and disease sever-
ity allows initiation of early and adequately tailored treat-
ment. This might prevent development of complications. 
And (3) insights into gender-specific differences in terms of 
treatment and adherence to treatment can improve disease 
management and foster a more individualized treatment ap-
proach. In this review, we summarize current knowledge 
about gender-specific differences in IBD and highlight the 
most clinically relevant aspects. © 2020 S. Karger AG, Basel
Introduction
The influence of the menstrual cycle on inflammatory 
bowel disease (IBD) course has been identified > 2 de-
cades ago [1]. So far, most sex-specific IBD studies have 
focused on pregnancy and childbirth. However, many 
more gender-specific differences (physiological and psy-
chological) seem to play an important role in IBD [2]. 
Gender-specific differences in IBD have been reported 
for disease presentation, disease course and complica-
tions, medical and surgical therapies, adherence, psycho-
social functioning, and psychiatric co-disorders. While 
for some aspects evidence is rather good, for others data 
are conflicting. In the era of personalized medicine and in 
light of potent biological treatment options, it appears ad-
equate to treat patients acknowledging their sex. Within 





specific differences in IBD and IBD management. We 
further highlight the most clinically relevant gender-spe-
cific aspects. Thereby we provide gastroenterologists with 
a roadmap of how to take gender into account when deal-
ing with IBD patients.
Epidemiology
Immune-mediated diseases typically show a female 
preponderance. Looking at all autoimmune diseases 
combined, 8 of 10 patients are females [3–5]. Such female 
predominance is particularly seen for diseases such as 
Sjogren’s syndrome or systemic lupus erythematosus. In 
gastrointestinal disease, primary biliary cholangitis and 
celiac disease are considerably more frequent in women 
than men. However, gender-specific differences are much 
less prominent in other immune-mediated disorders 
such as sarcoidosis, type 1 diabetes, and IBD [5, 6]. Type 
1 diabetes indeed is the only major organ-specific auto-
immune disorder without a strong female bias; in con-
trast, a considerable male excess is seen in patients aged 
15–40 years [7]. In IBD, gender-specific differences have 
been reported for Crohn’s disease (CD), but not ulcer-
ative colitis (UC), although data are conflicting and pos-
sibly depend on geographic areas. In Europe and the 
United States, CD prevalence appears to be higher in fe-
males than in males [8–13], while in Asia the opposite has 
been observed [14–16]. Early-onset CD (< 16 years) has 
been reported to be more frequent in males than females 
(20 vs. 12%) [17]. A recent large investigation revealed an 
even more complex relation between sex and IBD epide-
miology [18]. Young females at the age of 10–14 years 
showed a significantly lower risk for CD compared to 
men. A reduction in CD incidence of up to 20% has been 
reported. In contrast, females with an age of 25–29 years 
and particularly those older than 35 years are more prone 
to CD compared to their male counterparts. An increased 
risk of up to 40% has been observed [18]. Older males 
(> 45 years) appear to have a 20% higher incidence rate of 
UC compared to women [18]. These results have poten-
tial clinical implications. Since older male patients are 
more likely to suffer from the de novo UC, this diagnosis 
has to be considered particularly in elderly men with a 
chronic colonic inflammation of unknown etiology. 
However, data on potentially lower rates of IBD in young 
females should be interpreted cautiously, and diagnostic 
evaluation should be based on clinical presentation rath-
er than reported incidence rates. This is particularly true 
in light of the significantly increased diagnostic delay for 
female patients [19]. Such a diagnostic delay is a problem 
in the female IBD population and has potentially deleteri-
ous consequences. A diagnostic delay has been associated 
with increased rates of complications in IBD and higher 
risk for CD-related intestinal surgery [20].
Environmental Factors
The reasons for the abovementioned gender-specific 
differences in IBD epidemiology remain unclear; genet-
ic predisposition and different exposition to environ-
mental factors are possible explanations [21]. At least, 
appendectomy and smoking are associated with an in-
creased risk of CD in females [6, 22, 23]. Smoking has 
been a well-established and widely accepted risk factor 
for the development and progression of CD. While tra-
ditionally, smoking was more frequently observed in 
males across all age groups, this picture has changed 
quite dramatically in recent years. Numbers of smoking 
females, particularly those at younger age, have been 
steadily increasing. Currently, the highest smoking rates 
among IBD patients have been observed in middle-aged 
female CD subjects. The reported rate of 51.7% is higher 
than that seen in male counterparts as well as in the age- 
and sex-matched general population (26.6%) [24]. Ac-
cordingly, a Dutch study revealed that more women 
than men are current smokers in the IBD population 
[17]. Long time ago, the following dogma was estab-
lished and has been supported since: smoking is protec-
tive in UC, while it has deleterious effects in CD patients. 
However, the relation between smoking and IBD may be 
more complex than previously thought. Moreover, it ap-
pears to be gender-specific. Cosnes et al. [25] identified 
a protective effect of smoking in terms of UC develop-
ment and disease course in male patients only. More-
over, a decrease in the need for immunosuppressive 
treatment was seen in smoking male patients, but not 
females [25]. In CD, the deleterious effects of smoking 
were seen in females, but not in males [25]. Female IBD 
patients probably have the highest benefit from smoking 
cessation and should be encouraged to stop smoking, in 
both UC and CD. Given the excess rates of smoking CD 
females [24], smoking cessation programs should be tar-
geting those first.
A plethora of other gender-specific environmental fac-
tors potentially contribute to the development of IBD and 
disease complications. There appear to be considerable 
differences in terms of substance exposure between men 
and women, such as seen for drugs, chemical substances 
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related to occupation, sunlight and vitamin D, lifestyle 
factors including sleep, and shiftwork. However, the spe-
cific contribution of these factors to IBD has yet to be de-
termined in more detail. Of note, hormone exposure dur-
ing childhood, puberty, and menopause/andropause 
might play a role in IBD pathogenesis and disease course 
[6]. A clear gender-specific association with IBD has been 
established for antibiotics and appendectomy. Antibiotic 
use is more frequently reported among male patients, and 
boys may develop IBD more often after intake of antibiot-
ics [26]. Appendectomy has been linked to a higher risk 
of CD in female patients [22]. The microbiome has been 
increasingly recognized as a key player in the pathogen-
esis of IBD [27]. Gender-specific differences in the micro-
biota composition have been described [28]. However, 
their specific contribution to the development and dis-
ease course of IBD remains elusive.
Genetics
Female preponderance appears to be higher in familial 
compared to sporadic IBD cases (61 vs. 54%) [29]. More-
over, higher female-to-female transmission rates have 
been identified (compared to female-to-male transmis-
sion) [29]. This so-called female imprinting was specifi-
cally seen in CD. These findings shed light on a possible 
gender-specific genetic predisposition. In addition, sev-
eral known susceptibility gene variants have been linked 
to a gender-specific risk increase/decrease for IBD. 
Among those are R30Q DLG5 in CD (male-specific risk), 
IL-23R variant L310P (protects women, but not men 
from developing UC), and a single nucleotide polymor-
phism in the promoter region of IL-10 (increased risk for 
UC in females) [30–33]. Mechanistic explanations for 
these differences are however lacking. A further mecha-
nism for gender-specific differences in IBD genetics is re-
lated to X-chromosome abnormalities. X-chromosome 
abnormalities have been increasingly recognized as a pos-
sible contributor to autoimmunity [34, 35]. Loss of the 
X-chromosome in peripheral T- and B-lymphocytes has 
been associated with various immune-mediated disor-
ders such as primary biliary cholangitis, autoimmune 
thyroid disease, Reynolds syndrome, and systemic sclero-
sis [34, 36]. Loss of specific X-linked genes might result 
in the formation of autoantibodies [36]. If a similar mech-
anism is involved in IBD remains unknown. Of note and 
in accordance with this hypothesis, Turner syndrome, a 
disease where X-monosomy occurs in every cell, is associ-
ated with an increased rate of IBD [37].
Disease Activity and Phenotype
Data regarding the influence of gender on disease activ-
ity and disease course are conflicting: in some studies, no 
association has been found, while in others male sex has 
been identified as an independent prognostic factor for 
severe disease [38, 39]. Some studies – however – reported 
higher rates of remission in males and increased disease 
activity in females [40, 41]. Data are more consistent when 
it comes to extraintestinal manifestations (EIM). EIM rep-
resent 1 important aspect of disease burden and IBD activ-
ity and show a well-established gender-specific distribu-
tion. While peripheral joint affections and skin manifesta-
tions such as erythema nodosum, pyoderma gangrenosum, 
and eye disorders are more frequently encountered in fe-
males, primary sclerosing cholangitis and ankylosing 
spondylitis are more common in males [42]. Overall, EIM 
are more common in female IBD patients [17].
IBD phenotype and location also show gender-specif-
ic differences. Our Swiss group recently described an as-
sociation between sex and upper gastrointestinal tract in-
volvement (L4 according to Montreal classification) [43]. 
Male sex and young age were identified as the main risk 
factors for the involvement of the upper gastrointestinal 
tract in CD patients [43]. In another study, male sex has 
been significantly associated with ileal disease in CD (28 
vs. 20% in females) [17]. These findings suggest that IBD 
presents differently in men and women.
Disease Complications
For some IBD-related complications, a clear associa-
tion with male or female sex has been reported. Colon 
cancer is more frequent in male IBD patients [44]. In ad-
dition, mortality from colorectal cancer appears to be 
higher in men than in women [45]. On the other hand, 
pulmonary complications show a higher mortality in fe-
male CD patients [46]. For other complications, gender-
specificity is less clear and data are conflicting. A large 
prospective study from the Netherlands including 1,106 
patients with CD and UC and a mean follow-up of 7 years 
did not identify gender as prognostic factor for the devel-
opment of IBD complications. These complications in-
cluded surgery, cumulative medication use, disease re-
currence after surgery, and disease severity [38]. In con-
trast, a smaller study from Israel with 260 CD patients and 
a follow-up of 12 years revealed 2 independent prognostic 
factors for the development of complications: smoking 





with these findings, a study from Mayo Clinic revealed 
male sex as an independent predictive factor for major 
abdominal surgery including bowel resection and ileoce-
cal resection [47]. The Dutch IBD biobank – however – 
demonstrated increased rates of small bowel and ileocecal 
resection in female patients [17]. 
Osteopenia and osteoporosis represent possible IBD-re-
lated complications that are gender-specific. Counterintui-
tively, osteopenia and osteoporosis were more frequently 
reported in male (55.9%) than female IBD patients (29.6%) 
in a retrospective single-center study from Germany (with 
dual-energy X-ray absorptiometry scans available for 174 
patients). The gender-specific difference was mainly due to 
different rates of osteopenia rather than osteoporosis [48]. 
Similar findings have been reported in studies from Japan, 
the UK, and the Netherlands. Screening for the presence of 
osteopenia and osteoporosis is important in IBD patients 
and recommended by current society guidelines. Based on 
these findings, screening should be particularly promoted 
in male patients. However, a recent analysis of the Swiss IBD 
cohort revealed widely differing screening rates with rates 
as low as 11% in some centers [49].
Treatment and Adherence
Gender-specific differences are most impactful when 
it comes to IBD management. Indeed, use of and response 
to IBD treatment seem to vary between men and women 
regardless of intestinal disease activity, a fact that raises 
concerns about an adequate assessment of patients’ dis-
ease presentation and progression as well as the physi-
cian-derived integration of results from diagnostic test-
ing. Although data are limited, the following findings 
have been reported. Females are considered to receive no 
specific IBD treatment in a higher proportion than males 
[40]. In addition to medical treatment, major abdominal 
surgeries appear to be done more often in men than wom-
en, although data on intestinal resection and ileocecal re-
section are conflicting as previously mentioned [17, 47, 
50]. In the Dutch COIN study, there was no large gender-
specific difference regarding IBD treatment. Still, male 
CD patients received prednisone more often [17].
No clear trend has been identified regarding anti-tu-
mor necrosis factor outcome in 2 studies [51, 52]. How-
ever, a shorter time until loss of response has been as-
sociated with male sex in patients treated with adalim-
umab. In addition, dose intensification was more often 
needed in men than in women [51]. Male gender was 
identified as an independent predictor of loss of re-
sponse and need for dose intensification, together with 
known risk factors such as smoking, family history, iso-
lated colonic disease, EIM, and longer disease duration 
[51]. In contrast, a more recent investigation with a me-
dian follow-up of 6 years revealed that drug survival was 
higher in males compared to females (48.1 vs. 30.8%, p = 
0.016). This might be attributed to higher rates of side 















  surgery more
  frequent in males
Inconsistent data
  on ileocecal
  resection and small
  bowel resection
Higher rates of
  postoperative
  recurrence in
  females 
Compliance lower
  in females
Loss of response
  to ADA in males
Drug survival
  lower in females
Different
  pharmacokinetics
  due to gender-specific
  body composition
More side-effects
  in females
Females less often
  treated with anti-TNF
Fig. 1. Synopsis of gender-specific treat-
ment considerations. ADA, adalimumab.
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gender (together with smoking) was identified as an in-
dependent prognostic factor for nonadherence to bio-
logical treatment [54]. Neglecting these gender-specific 
aspects may potentially result in suboptimal treatment 
of men, women, or both. Figure 1 summarizes factors 
that need to be considered, when it comes to gender-
specific treatment approaches.
Psychological Factors
While data regarding epidemiology, disease course, 
and treatment can be conflicting, data on psychosocial 
functioning and psychiatric co-disorders in IBD seem to 
be quite consistent. The fact that prevalence of depression 
in IBD is higher in women than in men is not surprising 
given comparable results in the general population [55]. 
Women tend to use the healthcare system more often and 
absence from work seems to be higher [56]. Self-reported 
quality of life is lower in females than in males [56–58]. 
Fatigue represents an important clinical symptom that is 
often underrecognized among physicians involved in 
IBD care. Several studies have revealed that fatigue is 
highly frequent in IBD [59–62]. Of note, there is a well-
established gender-specific difference in terms of fatigue: 
female subjects tend to have a higher prevalence of fatigue 
and this finding is reported across all age groups (Swiss 
IBD cohort study, unpublished data). These findings are 
irrespective of the presence or absence of anemia, a typi-
cal contributor to the symptoms of fatigue [60]. More-
over, gender-specific difference in the prevalence of fa-
tigue is independent of underlying disease activity [60]. 
Both frequency and intensity of fatigue are more promi-
nent in the female population. IBD further has a negative 
impact on body image, more so in females than in males 
[63, 64]. Reduced sexual activity is more frequently re-
ported in female than male IBD patients (66.3 vs. 40.5%, 
p < 0.001) [64]. It is essential that these aspects are not 
neglected in daily clinical practice.
Clinical Implications of Gender Differences
The most important aspects that are relevant for gas-
troenterologists, when dealing with gender-specific is-
sues in daily practice, are summarized in Table 1. In the 
era of personalized medicine and in light of potent bio-
logical treatment options, it may not be adequate any-
more to treat patients without acknowledging their sex. 
Tailored treatment strategies for individual patients are 
needed, and for this, sex has to be taken into account as 
an important variable in addition to disease activity, phe-
notype, location, behavior, presence of complications, 
EIM, and so on. While sex as a modulating factor in IBD 
development and progression has been increasingly rec-
ognized in recent years, data are as of yet conflicting. 
Most evident and probably most clinically relevant are 
the following aspects: (1) smoking is a problem and risk 
factor particularly in females suffering from CD; (2) os-
teopenia is more frequently observed in men than wom-
en; and (3) side-effects from biologics are higher in fe-
males than males, which is presumably among the major 
driving forces for a lower treatment adherence in women. 
Based on these findings, clinicians should (1) assess 
Table 1. Most important aspects that are relevant in daily clinical 
practice when dealing with gender-specific issues
Dimension Gender-specific difference
Epidemiology Higher rates of CD in females in EU and US
Higher rates of CD in males in Asia
Young females with lower risk for CD, older 
females with higher risk
Older males with higher risk for UC
Environmental 
factors
Appendectomy and smoking in females
Antibiotic use in males
Genetics Female imprinting in familial IBD
Susceptibility gene variants such as IL-23R 





EIM more frequent in females
Upper GI involvement in males
Ileal disease more frequent in males
Disease  
complications
Higher risk and mortality for CRC in males
Higher mortality of pulmonary complications 
in females
Osteopenia more frequent in males
Treatment Male gender associated with loss of response 
to anti-TNF
Drug survival higher in males
More side-effects to anti-TNF in females
Adherence rates lower in females
Psychosocial  
factors
Depression more frequent in females
Self-reported QoL lower in females
Fatigue more frequent in females
CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory 
bowel disease; EIM, extraintestinal manifestations; IL, interleukin; 






smoking status in women in particular and encourage 
smoking cessation in this patient population; (2) screen 
for osteopenia/osteoporosis especially in male IBD pa-
tients; and (3) consider women in particular to be nonad-
herent to biological treatment. Side-effects should be par-
ticularly inquired. These 3 simple recommendations are 
a first step toward a gender-specific IBD management 
and will improve patient care.
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